Yogi Care Pharmaceutical Pvt Ltd.’s Post

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation 

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science. The company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.   Recently, AstraZeneca unveiled its new Bold Ambition during the Global Investor’s Day setting the stage for 2030! Aspiring to be pioneers in science, focused on transform patient outcomes, by 2030, globally we will deliver 20 new medicines, industry leading growth and aim to be carbon negative.   In India, we have recently announced our financial results for FY 2023-24 with 29% growth in revenue, which is one of our strongest years of performance. We owe this our talented, committed and passionate group of employees who go above and beyond in terms of achieving greater milestones every single day to transform the lives of patients. Proud to be part of a company that is unlocking the power of what science can do for people, society and the planet.   Read more here: https://lnkd.in/gtJHuUeK   #ScienceCan #AZProud

Result of excellent leadership and commitment.

💡 Meanwhile, in major pharmaceutical news...What's the future of healthcare? 👩🔬 After launching several new, effective medicines and vaccines this year, Paul Hudson and his team at Sanofi have also received regulatory approval for a new treatment in lung disease. 🤖 Amongst these developments, they have also launched Modulus, a new type of AI powered factory that produces multiple vaccines and medicines at a faster rate which will only help the response time for future health crises. As Sanofi looks to focus on developing new medicines and treatments, they look to capitalize on becoming a pure-play biopharma organization by spinning off its consumer health business. 🔬 What does this mean for the industry...? - Innovation: They are leading the way in medicine manufacturing with AI, bringing a positive sign for the industry. - Patient Access: They are improving the health and well-being of millions as they strive for groundbreaking new treatments. - Industry Consolidation: Sanofi's decision to focus solely on biopharma could lead further organizations to specialize and focus on their core competencies. ⁉ What other impacts can you see Sanofi having on the industry? Is Big Biotech on the way? What are you most excited about in the future of healthcare? 🗯 Share your thoughts below! #HealthcareFuture, #Innovation, #PatientCentered

We finished Q3 strong, with broad-based, double-digit sales growth propelled by our launches of best-in-class medicines and vaccines.       The momentum of our Sanofi pipeline continues this quarter, with a sustained cadence of positive phase 3 data and major regulatory approvals, including three in a row - EU, US & China - for the first-ever biologic for certain adults with uncontrolled Chronic Obstructive Pulmonary Disease.      Our modernization is taking shape every day at an incredible pace. Last month, we inaugurated Modulus, the first AI-powered factory of the future. Modulus can manufacture up to four vaccines or biomedicines at a time, with the unique ability to quickly adapt in a matter of days in response to health challenges around the world. It’s one factory, but with infinite possibilities.      We’re also progressing with our strategy to create a focused player in Consumer Healthcare, giving Opella the opportunity to thrive as a global leader and paving the way for Sanofi to become a pure-play, science-driven biopharma company.       Looking to the future, I’m confident in the course we’ve charted and excited about what’s to come. Not only for Sanofi, but for the millions of people around the world who are counting on us.   Read more on our Q3 results here: https://lnkd.in/ejgVYWYN #SanofiResults #Science #Innovation

What’s meaningful to my work here at AstraZeneca? Beyond our dedication to advancing healthcare in Vietnam and ensuring equitable access to the latest and most effective treatments over our 30-year presence in the country, it is the meaningful collaboration and mutual trust we nurture with our stakeholders and partners that truly stand out. On September 30, 2024, I had the privilege of meeting with Vice Minister of the Ministry of Health, Mr. Do Xuan Tuyen, to discuss our ongoing and future contributions to Vietnam’s healthcare landscape. During this meeting, we outlined AstraZeneca Vietnam's key activities in: 💡Pharmaceutical Research and Development 💡Technology Transfer Projects aimed at producing advanced drugs locally. 💡Community Investment Programs aimed at creating an equitable and sustainable healthcare system, enhancing Vietnamese patients' access to advanced medications and treatments. We reaffirmed our alignment with Vietnam’s National Strategy for Pharmaceutical Industry Development and the National Program for Domestic Pharmaceutical Production by 2030, with a vision extending to 2045. Our goal is to support Vietnam in becoming a central hub for producing original brand-name drugs in the ASEAN region. Vice Minister Do Xuan Tuyen expressed high appreciation for AstraZeneca’s contributions and support over the years, particularly during the Covid-19 pandemic. He acknowledged our efforts in technology transfer, clinical trials, disease prevention and control, and our commitment to building a sustainable healthcare system. I felt both supported and encouraged after our discussion. With continued collaboration and support from the Ministry of Health, I am confident that we can achieve remarkable outcomes that benefit our people, society, and the planet. Picture below was taken with Vice Minister Do Xuan Tuyen in Hanoi. More information in Vietnamese: https://lnkd.in/gUH-auz3

How can social media intelligence support blockbuster launches? CREATION.co’s insights reveal key strategies: increase data awareness, engage at major congresses, and address educational gaps. Learn how to drive successful blockbuster launches with HCP social media intelligence by reading Jessica Fernandes’ new article looking at GSK’s #depemokimab for severe #asthma. #Pharma #MedEd #HCPInsights Follow CREATION.co to keep up with our latest research

#Asthma_And_COPD Market Insights, Trends & Future Development Status Recorded during 2023-2032 >> https://lnkd.in/dJUAemHN #Asthma and COPD (Chronic Obstructive #Pulmonary Disease) are chronic respiratory #conditions affecting the #airways and making #breathing difficult. While they #share some similarities, they have #distinct #characteristics and underlying causes. AstraZeneca GSK F. Hoffmann-La Roche Ltd Novartis Merck Group Abbott Amgen Actavis LLC AptarGroup S.A. AUROBINDO PHARMA LTD Boehringer Ingelheim Cipla Glenmark Pharmaceuticals #biotechnologies #marketgrowth #asthmacare #copd #healthcareindustry #pharmaceuticalproducts #humancare

When I shared with my team the news from Boehringer Ingelheim earlier this month about caps on inhaler prices, I also said it's only a matter of time until we see more follow suit! This week AstraZeneca jumped into the fun! This is all playing out just like we saw with insulin in the past year What do we know: ➡ Both BI and AZ will cap out of pocket inhaler costs at $35 starting 6/1/24. ➡ We don't have details on the how yet. Anticipating the caps will leverage co-pay assistance cards like they did for insulin. ➡ Much like insulin, decrease in list prices at a later date (1/1/25) are also coming most likely due to AMP cap removal These announcements are great, but many are left out until we can get GSK (big player here), Teva, and Merck on board too! https://lnkd.in/gKbtuKTe #pharmacybenefits #pharmacists #asthma #copd #inhalers #costcap #savings